Jinzhang Chen

机构：Nanfang Hospital, Zhongda Hospital Southeast University, Southern Medical University · ORCID：0000-0003-4964-2218

发表论文 72 篇 · 总被引 1018 次 · h-index 16

代表论文

• Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study (2024 · EClinicalMedicine · 被引 156)
• Arterial chemotherapy for hepatocellular carcinoma in China: consensus recommendations (2023 · Hepatology International · 被引 57)
• A novel engineered IL-21 receptor arms T-cell receptor-engineered T cells (TCR-T cells) against hepatocellular carcinoma (2024 · Signal Transduction and Targeted Therapy · 被引 38)
• Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: a multicenter, single-arm, phase 2 trial (2024 · BMC Medicine · 被引 33)
• Tyrosine kinase inhibitors, immune checkpoint inhibitors combined with hepatic arterial infusion of oxaliplatin and raltitrexed versus oxaliplatin, 5-fluorouracil and leucovorin for intermediate and advanced hepatocellular carcinoma: A retrospective study (2023 · International Immunopharmacology · 被引 17)
• Cadonilimab (PD-1/CTLA-4) in combination with lenvatinib in unresectable hepatocellular carcinoma (uHCC): A retrospective real-world study (2024 · Heliyon · 被引 9)